CD18 antibody [YFC118.3] (Azide free)
GTX76241
ApplicationsFlow Cytometry, ImmunoPrecipitation, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen
Product group Antibodies
ReactivityCanine, Human
TargetITGB2
Overview
- SupplierGeneTex
- Product NameCD18 antibody [YFC118.3] (Azide free)
- Delivery Days Customer9
- Application Supplier NoteIHC-Fr: 1/1,000-1/5,000. FACS: 1/50-1/100. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsFlow Cytometry, ImmunoPrecipitation, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone IDYFC118.3
- ConjugateUnconjugated
- Gene ID3689
- Target nameITGB2
- Target descriptionintegrin subunit beta 2
- Target synonymsCD18; cell surface adhesion glycoprotein (LFA-1/CR3/P150,959 beta subunit precursor); complement component 3 receptor 3 and 4 subunit; complement receptor C3 beta-subunit; integrin beta chain, beta 2; integrin beta-2; integrin, beta 2 (complement component 3 receptor 3 and 4 subunit); LAD; LCAMB; leukocyte cell adhesion molecule CD18; leukocyte-associated antigens CD18/11A, CD18/11B, CD18/11C; LFA-1; MAC-1; MF17; MFI7; truncated integrin beta-2
- HostRat
- IsotypeIgG2b
- Protein IDP05107
- Protein NameIntegrin beta-2
- Scientific DescriptionThis gene encodes an integrin beta chain, which combines with multiple different alpha chains to form different integrin heterodimers. Integrins are integral cell-surface proteins that participate in cell adhesion as well as cell-surface mediated signalling. The encoded protein plays an important role in immune response and defects in this gene cause leukocyte adhesion deficiency. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2014]
- ReactivityCanine, Human
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. Sindrilaru A et al., 2011 Mar, J Clin InvestRead more